株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の子宮内膜症市場

Endometriosis

発行 Global Industry Analysts, Inc. 商品コード 236863
出版日 ページ情報 英文 181 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.88円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界の子宮内膜症市場 Endometriosis
出版日: 2018年01月01日 ページ情報: 英文 181 Pages
概要

当レポートでは、世界の子宮内膜症市場について調査し、市場の概要と成長動向、製品概要、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 子宮内膜症:イントロダクション
    • 既存薬の有効性と安全性の低さがアンメットニーズに
    • 市場における主な子宮内膜症治療薬
    • パイプラインレビュー
    • 今後数年は着実に成長
    • 新興の治療法
    • 世界の認知度キャンペーン
    • 医療費高等が持続的機会に
    • 先進国が主な収益貢献地域
    • 途上国は大きな成長の可能性
    • 安定した経済シナリオ
  • 子宮内膜症とその治療法
    • イントロダクション
    • 女性における子宮内膜症の発症
    • 原因と兆候
    • 子宮内膜症の種類
    • 主な診断技術
    • 患者カウンセリング
    • 再発
    • 子宮内膜症と癌
    • 子宮内膜症研究センター
  • 子宮内膜症の治療
    • 子宮内膜症と利用可能な治療法
    • 子宮内膜症の治療メカニズム
  • 非ステロイド抗炎症製薬(NSAID)
  • 非ホルモン治療
  • 外科技術
  • 補完治療
  • 治験/製品革新と認可
  • 製品概要
  • 近年の業界活動
  • 主要企業
    • AbbVie Inc.
    • アステラス製薬株式会社
    • AstraZeneca Plc
    • Bayer AG
    • Debiopharm Group
    • Evotec AG
    • キッセイ薬品工業株式会社
    • Neurocrine Biosciences, Inc.
    • ObsEva SA
    • Pfizer, Inc.
    • Repros Therapeutics, Inc.
    • Roivant Sciences GmbH
    • 武田薬品工業株式会社
    • ValiRx plc
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
目次
Product Code: MCP-6433

This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Debiopharm Group
Evotec AG

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Endometriosis: An Introductory Prelude
  • Endometriosis Facts in a Nutshell
  • Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
  • Key Endometriosis Drugs on the Market
    • Table 1: Leading Endometriosis Drugs on the Market (2017E): Percentage Breakdown of Revenues for Depo-Provera, Lupron, Visanne, Zoladex and Others (includes corresponding Graph/Chart)
  • The Pipeline Review
    • Key Endometriosis Drugs in the Pipeline: 2017
  • Steady Growth Expected Over the Next Few Years
  • Emerging Treatment for Endometriosis & Endometrial Cancer
  • Global Awareness Campaigns and Efforts
  • Uptrend in Healthcare Expenditure Creates Substantial Opportunities
    • Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart)
    • Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart)
  • Developed Regions Remain Primary Revenue Contributors
    • Table 4: Developed Regions Account for over 90% Share of World Endometriosis Drugs Market: Percentage Breakdown of Value Sales for Developed Regions and Developing Regions (2017E & 2022P) (includes corresponding Graph/Chart)
  • Developing Regions Exhibit Immense Growth Potential
  • Stable Economic Scenario to Augment Market Prospects
    • Table 5: World Real GDP Growth Rates in % (2016-2018P): Breakdown by Country/Region (includes corresponding Graph/Chart)

2. ENDOMETRIOSIS & ITS TREATMENT - AN OVERVIEW

  • Introduction
  • Occurrence of Endometriosis in Women
  • Causes and Symptoms
  • Causes
    • Estrogen Theory
    • Mullerianosis Theory
    • Retrograde Menstruation Theory
    • Coelomic Metaplasia Theory
    • Hereditary Factors
    • Environmental Factors
      • Dioxin Behavior in the Body
    • Birth Defects
    • Other Causes
  • Symptoms of Endometriosis
    • Reasons for Pain due to Endometriosis
    • Endometriosis and Infertility
  • Kinds of Endometriosis
  • Reproductive Area Endometriosis
  • Uterosacral/Presacral Nerve Endometriosis
  • Cul-de-Sac ("Pouch of Douglas") Endometriosis
  • Gastrointestinal Endometriosis
  • Pleural (lung/chest cavity/diaphragmatic) Endometriosis
  • Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
  • Skin Endometriosis
  • Sciatic Endometriosis
  • Stages of Endometriosis
  • Diagnosis of Endometriosis
  • Major Diagnostic Techniques
  • Pelvic Exam
  • Laparoscopy
  • Other Diagnostic Procedures
  • A New Non-invasive Test for the Diagnosis of Endometriosis
  • Endometriosis Markers
  • Counseling of patients
  • Recurrence of Endometriosis
  • Endometriosis & Infertility
  • Miscarriage
  • Endometriosis & Thyroid Autoimmunity
  • Relationship between Endometriosis and Autoimmune Disease
  • Endometriosis & Cancer
  • Associations & Research Centers
  • The Endometriosis Association
  • Endometriosis Research Center

3. TREATMENT OF ENDOMETRIOSIS

  • Endometriosis & Available Treatment Options
  • Endometriosis Treatment Mechanisms: In a Nutshell

I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

  • II. Hormonal Therapy
  • Gonadotropin Releasing Hormone (Gnrh) Agonists
    • Select Major GnRH-Agonists for Endometriosis Treatment
    • Lupron, Zoladex and Synarel - The Major Drugs
    • AbbVie's Lupron(r) (Leuprorelin)
    • AstraZeneca's Zoladex(r) (Goserelin)
    • Pfizer's Synarel (Nafarelin Acetate)
  • Add-back Medication
  • Progestogens
    • Select Major Progestins for Endometriosis Treatment
    • Combined Oral Contraceptive Pill
    • Danazol and Other Suppressive Steroids
  • Chinese Herbs - More Effective than Danazol or Gestrinone
  • Aromatase Inhibitors

III. Non-hormonal Therapy

  • Anti-Angiogenic Agents
  • Selective COX-2 Inhibitors
  • TNF-Alpha Inhibitors

IV. Surgical Techniques

V. Complementary Therapies

  • Long-term Approach to Pain
  • Lifestyle Modifications
  • Chinese Herbs
  • Treatment for Endometriosis-related Infertility
  • Hormonal Treatment
    • Minimal to Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Surgical Treatment
    • Minimal-Mild Endometriosis
    • Moderate-Severe Endometriosis
  • Treatment for Ovarian Endometriosis
  • Surgical Vs. Medicinal Interventions
    • Medicinal Interventions
      • Advantages
      • Disadvantages
    • Surgery
      • Advantages
      • Disadvantages
  • In-vitro Fertilization
  • Other Treatment

4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS

  • AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix
  • AbbVie Announces Results from Replicate Phase 3 Extension Studies for Elagolix
  • Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan's Efficacy in Treating Symptomatic UF
  • ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109
  • Repros Keeps Proellex(r) Development Program on Partial Clinical Hold of FDA
  • Aeterna Zentaris Halts Development of Zoptrex(tm)
  • Evotec and Bayer's Endometriosis Alliance Portfolio Advances into Phase I Clinical Development
  • ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2109 to Treat UF
  • Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF
  • Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-Associated Pain
  • Repros Therapeutics' Achieves Positive Results from Proellex Phase II Study
  • ValiRx Bags European Patent for VAL201
  • Virexxa Receives FDA Clearance to Proceed to Phase II
  • OBE2109 by ObsEva Receives IND Clearance
  • Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies
  • AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix
  • ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201
  • Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment
  • Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution
  • Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment
  • Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy
  • Teleflex to Showcase its Surgical Solutions for Endometriosis
  • ValiRx Plc Receives Patent Grant for VAL201

5. RECENT INDUSTRY ACTIVITY

  • AstraZeneca Bags Commercial Rights to Zoladex
  • Astellas Pharma to Acquire Ogeda
  • Roivant Establishes New Global Headquarters in Basel
  • Takeda and Roivant Partner to Form Myovant
  • Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy
  • ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109

6. FOCUS ON SELECT GLOBAL PLAYERS

  • AbbVie Inc. (USA)
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca Plc (UK)
  • Bayer AG (Germany)
  • Debiopharm Group (Switzerland)
  • Evotec AG (Germany)
  • Kissei Pharmaceutical Co., Ltd. (Japan)
  • Neurocrine Biosciences, Inc. (USA)
  • ObsEva SA (Switzerland)
  • Pfizer, Inc. (USA)
  • Repros Therapeutics, Inc. (USA)
  • Roivant Sciences GmbH (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • ValiRx plc (UK)

7. GLOBAL MARKET PERSPECTIVE

    • Table 6: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 8: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Largest Market for Endometriosis Drugs
    • Endometriosis Associations Increase Awareness
    • Newer Diagnostic Methods Yet to Expand Across the Country
    • Key Endometriosis Drugs on the Market
    • Product Launches/Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 9: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 10: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Product Launch
    • Key Players
  • B. Market Analytics
    • Table 11: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 12: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Clinical Trial
    • Key Players
  • B. Market Analytics
    • Table 13: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 14: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analysis
    • Table 15: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 16: European Historic Review for Endometriosis Drugs by Geographic Region/ Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 17: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Programmes to Maintain Endometriosis Database
  • B. Market Analytics
    • Table 18: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 19: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Clinical Trials
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 20: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 21: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 22: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 23: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Product Launches/Clinical Trials
    • Key Players
  • B. Market Analytics
    • Table 24: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 26: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Product Launches/Clinical Trials
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 28: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • The Rapidly Growing Market
    • Endometriosis Therapeutics in Australia
  • B. Market Analytics
    • Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 32: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 33: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Back to Top